IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This will be a phase II trial testing if the combination of stereotactic ablative body
radiotherapy (SABR) and L19-IL2 improve the progression-free survival in patients with
limited metastatic non-small cell lung cancer (NSCLC). The trial consists of one cohort with
two arms; C-arm and an E-arm.
Patients with oligometastatic disease will receive SABR to minimal 1 and max all metastatic
sites (max 5 sites irradiated) and patients with diffuse metastatic lesions (6 to max 10)
will receive radiotherapy to max 5 sites. In the experimental arm, immunotherapy will be
given after irradiation.
Phase:
Phase 2
Details
Lead Sponsor:
Maastricht University
Collaborators:
Academisch Ziekenhuis Maastricht Catholic University of the Sacred Heart Centre Oscar Lambret Cliniques universitaires Saint-Luc- Université Catholique de Louvain Erasmus Medical Center Gasthuis Zusters Antwerpen Heidelberg University Institut du Cancer de Montpellier - Val d'Aurelle KU Leuven The Netherlands Cancer Institute University College, London University Ghent University Hospital Dresden University Hospital Tuebingen University Medical Center Nijmegen